Clinical evolution at 30 days in the different treatment groups. by Ismael Francisco Aomar-Millán (14838595)

Subjects:

SaFi, laboratory, radiology, vaccine status, and inpatient treatment data. by Ismael Francisco Aomar-Millán (14838595)

Subjects:

Adverse pregnancy outcomes recorded among study participants. by Seth Amponsah-Tabi (13949142)

Subjects:

Probability of medical discharge at 60 days in the different treatment groups. by Ismael Francisco Aomar-Millán (14838595)

Subjects:

Quality of Antenatal care and adverse maternal and fetal outcomes. by Seth Amponsah-Tabi (13949142)

Subjects:

Distribution of different levels of quality of antenatal care provided to study participants. by Seth Amponsah-Tabi (13949142)

Subjects:

Sociodemographic and reproductive factors associated with good quality antenatal care. by Seth Amponsah-Tabi (13949142)

Subjects:

Sociodemographic and reproductive characteristics of the study participants. by Seth Amponsah-Tabi (13949142)

Subjects:

Comorbidities and severity scales at admission for the different treatment groups. by Ismael Francisco Aomar-Millán (14838595)

Subjects:

S1 Data - by Seth Amponsah-Tabi (13949142)

Subjects:

Probability of remaining as an inpatient at 30 days in the different treatment groups. by Ismael Francisco Aomar-Millán (14838595)

Subjects:

Probability of medical discharge at 30 days in the different treatment groups. by Ismael Francisco Aomar-Millán (14838595)

Subjects:

Probability of remaining as an inpatient at 60 days in the different treatment groups. by Ismael Francisco Aomar-Millán (14838595)

Subjects:

<i>sirB⁻</i>, Vic1, Vic2 and T6SS-double mutants showed decreased virulence in planta. by Johanna Nykyri (124297)

A BMP7 Variant Inhibits Tumor Angiogenesis <i>In Vitro</i> and <i>In Vivo</i> through Direct Modulation of Endothelial Cell Biology by Courtney M. Tate (555115)

“…Importantly, in an <i>in vivo</i> angiogenic plug assay that serves as a measurement of angiogenesis, BMP7v significantly decreased hemoglobin content indicating inhibition of neoangiogenesis. …”

The residual signaling activity of γ2-MSH and γ3-MSH in plasma is MCR specific and plasma stability decreased compared to CNS stability. by Karin Löw (8805416)

Supplementary Material for: Somatic variants and exon-level copy number changes in five hyperplastic-stage oral leukoplakias. by Anne A. (13992672)

“…Oral leukoplakia (OL), an oral potentially malignant disorder begins with a hyperplastic/hyperkeratotic stage at which no genome-scale somatic single nucleotide variant profiles have been described so far. …”

Supplementary Material for: Somatic variants and exon-level copy number changes in five hyperplastic-stage oral leukoplakias. by Anne A. (13992672)

“…Oral leukoplakia (OL), an oral potentially malignant disorder begins with a hyperplastic/hyperkeratotic stage at which no genome-scale somatic single nucleotide variant profiles have been described so far. …”

Supplementary Material for: Somatic variants and exon-level copy number changes in five hyperplastic-stage oral leukoplakias. by Anne A. (13992672)

“…Oral leukoplakia (OL), an oral potentially malignant disorder begins with a hyperplastic/hyperkeratotic stage at which no genome-scale somatic single nucleotide variant profiles have been described so far. …”

Supplementary Material for: Somatic variants and exon-level copy number changes in five hyperplastic-stage oral leukoplakias. by Anne A. (13992672)

“…Oral leukoplakia (OL), an oral potentially malignant disorder begins with a hyperplastic/hyperkeratotic stage at which no genome-scale somatic single nucleotide variant profiles have been described so far. …”